India approves its first dengue vaccine QDENGA after DCGI clearance
The Drug Controller General of India (DCGI) granted market authorisation to QDENGA, making it India's first approved dengue vaccine.
The vaccine, developed by Takeda and manufactured for the Indian market by Takeda Biopharmaceuticals India, is approved for people aged 4 to 60 years.
Unlike some earlier-generation dengue vaccines, QDENGA does not require pre-vaccination screening for prior dengue infection, widening its usable population.
It is administered as two subcutaneous injections of 0.5 ml each, given three months apart.
Globally, QDENGA has been approved in over 40 countries since its 2022 launch, with tens of millions of doses distributed.
Dengue as a vector-borne disease and India's burden
Dengue is caused by four distinct virus serotypes (DENV-1 to DENV-4) transmitted by the Aedes aegypti mosquito, which breeds in stagnant fresh water and bites during the day. Infection with one serotype gives lifelong immunity to that serotype but only partial, temporary protection against the others — meaning a person can be infected multiple times, and a second infection with a different serotype carries a higher risk of severe dengue (dengue haemorrhagic fever/dengue shock syndrome). India carries a large share of the global dengue burden, and the disease is a Notified programme under the National Centre for Vector Borne Diseases Control (NCVBDC, formerly NVBDCP) under the Ministry of Health and Family Welfare.
Key Details
- Four serotypes: DENV-1, DENV-2, DENV-3, DENV-4; multi-serotype exposure raises severe-dengue risk.
- Vector: Aedes aegypti (day-biting, container-breeding mosquito); also transmits chikungunya, Zika and yellow fever.
- Nodal body: National Centre for Vector Borne Diseases Control (NCVBDC), Ministry of Health and Family Welfare.
- India recorded over 2.3 lakh dengue cases in a recent year, among the highest case counts globally.
Because reinfection with a different serotype is the main driver of severe disease, a vaccine had to protect against all four serotypes simultaneously — which is exactly the design basis of QDENGA (see below).
Vaccine platform: live-attenuated tetravalent vaccine
QDENGA (scientific name TAK-003) is a live-attenuated tetravalent vaccine — it contains weakened versions of all four dengue serotypes built on a DENV-2 genomic backbone, designed to trigger immunity against all four strains at once. This is a different platform from purely inactivated or subunit vaccines, and its tetravalent design specifically targets the multi-serotype reinfection risk that makes dengue dangerous. The World Health Organization prequalified TAK-003 in May 2024 — only the second dengue vaccine to receive WHO prequalification — which allows procurement by UN agencies such as UNICEF and PAHO. WHO recommends the vaccine primarily for children aged 6–16 years in high-transmission settings, whereas India's DCGI has approved a broader 4–60 age band for the domestic market.
Key Details
- Platform: live-attenuated, tetravalent (all four DENV serotypes), DENV-2 backbone.
- WHO prequalification: May 2024 (second dengue vaccine to be prequalified, after Dengvaxia).
- Regulatory approver in India: DCGI, under the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare.
- Clinical efficacy in trials: roughly 61% against virologically confirmed dengue and around 84% against dengue-related hospitalisation in endemic settings.
The DCGI clearance is a market-authorisation decision under India's drug regulatory framework (CDSCO/DCGI), distinct from WHO prequalification — India can set its own approved age range and use conditions independent of WHO's global recommendation, which is why the Indian approval (4–60 years) is broader than WHO's advisory (6–16 years).
Public health significance: vaccines as a vector-control complement
Historically, India's dengue strategy has relied on vector control (source reduction, larvicides, fogging) and clinical case management, since no vaccine was previously licensed for the general population here. A locally available, broadly approved vaccine adds a second pillar — immunisation — to the existing vector-control-based National Centre for Vector Borne Diseases Control strategy, relevant to Sustainable Development Goal 3 (good health and well-being) and India's National Health Policy emphasis on communicable disease control.
Key Details
- Prior approach: source reduction, insecticide-treated nets/fogging, and clinical management (no fluid-replacement-specific antiviral exists for dengue).
- Complementary role: vaccination does not replace vector control since non-vaccinated individuals and breakthrough infections remain possible.
- Urbanisation, climate change and monsoon-linked stagnant water are commonly cited factors sustaining India's dengue burden.
The DCGI approval opens the door for QDENGA to be considered for inclusion in state or private immunisation programmes as a complement to existing vector-control measures, though it is not yet part of India's Universal Immunisation Programme.
- QDENGA (TAK-003) approved by DCGI for ages 4–60 years; two 0.5 ml subcutaneous doses, three months apart.
- No pre-vaccination dengue screening required before administration.
- WHO prequalified TAK-003 in May 2024 — the second dengue vaccine to achieve this status.
- Approved in more than 40 countries globally since its 2022 launch, with tens of millions of doses distributed worldwide.
- Trial efficacy: approximately 61% against confirmed dengue, approximately 84% against hospitalisation.